PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism; Venous thrombosis
- Focus Therapeutic Use
- Acronyms PARADOX
- 19 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 31 Dec 2015 Planned primary completion date changed from 1 May 2019 to 1 Jan 2020, according to ClinicalTrials.gov record.
- 22 Sep 2015 Planned primary completion date changed from 1 Apr 2019 to 1 May 2019 as reported by ClinicalTrials.gov.